In a recent issue of Intensive Care Medicine, we read with great interest the article by Moyon et al. [
1] who retrospectively studied the outcomes of immunocompromised patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation (VA-ECMO). They showed that immunocompromised patients undergoing VA-ECMO treatment have a high 90-day mortality rate of 70%, and that an immunocompromised status is independently associated with mortality. Since these are important findings for evaluating appropriate indications for VA-ECMO in immunocompromised patients, we appreciate this research for providing clinically useful information. However, several factors potentially affecting their results should be discussed. …